ACAD vs ALC
ACADIA Pharmaceuticals Inc. vs Alcon Inc — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
| Metric | ACAD | ALC |
|---|
| AI Score |
69
|
68
|
| Price |
$29.41
|
$75.39
|
| P/E Ratio |
13.07×
|
45.39×
|
| ROE |
31.9%
|
4.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
54.9%
|
| Debt / Equity |
0.06×
|
0.24×
|
| Dividend Yield |
0.0%
|
0.5%
|
| RSI (14) |
78.4
|
73.4
|
| Beta |
0.845
|
0.703
|
| Expected Upside |
—
|
+11.3%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus ALC.
ACAD leads by 1 points.
ACAD scores 69/100 (Buy) versus ALC at 68/100 (Buy).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical